Orbis Investment trims Genmab (GMAB) stake to 4.85% of voting rights
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S reports a major shareholder update involving Orbis Investment Management Limited. As of April 13, 2026, Orbis controlled the voting rights to 3,114,318 Genmab shares, equal to 4.85% of the share capital and voting rights. This represents a small decrease from a previously reported level of about 5.01%. The notice is made under Section 30 of the Danish Capital Markets Act and confirms Orbis’ position as a significant, but minority, shareholder in Genmab.
Positive
- None.
Negative
- None.
Key Figures
Orbis voting rights: 3,114,318 shares
Current ownership percentage: 4.8471%
Previous ownership percentage: 5.0141%
+1 more
4 metrics
Orbis voting rights
3,114,318 shares
Voting rights controlled in Genmab as of April 13, 2026
Current ownership percentage
4.8471%
Orbis’ voting rights as a share of total voting rights
Previous ownership percentage
5.0141%
Orbis’ voting rights at prior notification
Total issuer voting rights
64,250,721
Total number of Genmab voting rights used for calculation
Key Terms
major shareholder announcement, Danish Capital Markets Act, voting rights, financial instruments, +1 more
5 terms
Danish Capital Markets Act regulatory
"announces under reference to Section 30 of the Danish Capital Markets Act"
A national law that sets the rules for trading, reporting and oversight of securities and financial markets in Denmark; think of it as the official rulebook that governs how companies, investors and intermediaries must behave when raising capital or trading shares. It matters to investors because it mandates information disclosure, market transparency and conduct standards that reduce fraud, make prices more reliable and protect shareholder rights, helping investors judge risks and make informed decisions.
voting rights financial
"through shares controlled the voting rights to 3,114,318 shares in Genmab A/S"
Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.
financial instruments financial
"An acquisition or disposal of financial instruments"
Financial instruments are assets or contracts that hold monetary value and can be bought, sold, or traded. They serve as tools for investors to grow, protect, or transfer money, much like how a ticket or voucher can be used to access goods or services. These instruments help individuals and organizations manage financial goals and risks across different markets and economic conditions.
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF APRIL 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated April 14, 2026 | ||||
| 99.2 | Orbis Shareholder Notification | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: April 14, 2026
Exhibit 99.1
Major Shareholder Announcement
Company Announcement
•Major shareholder announcement for Genmab A/S
COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,114,318 shares in Genmab A/S, which amounts to 4.85% of the share capital and voting rights in Genmab A/S.
The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 23 Page 1/1 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Shareholder Shareholder 1 / 3 Master data Standard form for notification of major holdings 3. Details of person subject to the notification obligation: Name Allan & Gill Gray Foundation Address Redwood House, St Julian Avenue, GY1 1WA, St Peter Port, GG National ID-number Guernsey Registration Number: 32 Email address gpolkinghorne@allangillgrayphilanthropies.org 4. Full name of shareholder (if different from 3.) The boxes in sections (1-6) and section (8) in the standard form must always be filled out. Section 3 and 4 can be found at the beginning of the form, under master data. Then, please fill out the sections in the standard form for the relevant type of financial instrument. For notification regarding shares go to section (7.1) in the standard form. For notification regarding financial instruments in accordance with section 39(2)(1) of the Capital Markets Act, go to section (7.2) in the standard form. For notification regarding financial instruments in accordance with section 39(2)(2) of the Capital Markets Act, go to section (7.3) in the standard form. In case of proxy voting, fill out section (9) in the standard form. Section 6 is completed automatically when you report your holding in item 7. If there is a holding from a previous notification, this must be indicated below and entered manually. In case of proxy voting, fill out section (9) in the standard form. Other (please specify): An event changing the breakdown of voting rights or share capital An acquisition or disposal of financial instruments An acquisition or disposal of voting rights or share capital 2. Reason for the notification (please tick the appropriate box or boxes): 5. Date on which the threshold was crossed or reached 13-04-2026 6. Total positions of the person subject to the notification obligation: Voting rights: Resulting situation on the date on which threshold was crossed or reached Voting rights attached to shares in % (total of 7.1.A) 4,8471 % Voting rights through financial instruments in % (total of 7.2.A + 7.3.B) 0,00 % The total of both in % (7.1.A + 7.2.A + 7.3.A) 4,8471 % Position of previous notification (if applicable) Voting rights attached to shares in % (total of 7.1.A) 5,0141 % Voting rights through financial instruments in % (total of 7.2.A + 7.3.B) 0,00 % The total of both in % (7.1.A + 7.2.A + 7.3.A) 5,0141 % Share capital: Resulting situation on the date on which threshold was crossed or reached Share capital attached to shares in % (total of 7.1.B) 0,00 % Share capital attached to shares in % (total of 7.1.B) 0,00 % Share capital attached to shares in % (total of 7.1.B) 0,00 % Position of previous notification (if applicable) 6.A Information on the issuer Total number of voting rights of issuer 64.250.721
Shareholder Shareholder 2 / 3 Total share capital in issuer 64.250.721 7. Specify type of holding Please check the categories below that are relevant for your holding. You can select multiple categories if your portfolio includes different types of instruments or rights. Choose between: Direct shareholding (section 7.1), if you own shares in the company Financial instruments with the right to acquire shares (section 7.2), such as options or forward contracts that give you the right to buy or subscribe for shares Financial instruments with similar economic effect (section 7.3), such as cash-settled derivatives or other instruments that reflect the value of the shares without physical delivery For each category, you must specify whether your holding relates to (A-sections) and/or (B-sections).voting rights share capital If you are unsure which categories apply to you, we recommend that you consult capital markets legislation or seek advice. 7.1 Shares according to section 38 of the Capital Markets Act 7.1.A Holding of voting rights attached to shares ISIN code GENMAB A/S Number of voting rights Voting rights stated in % Voting rights which the person subject to the notification obligation holds directly or indirectly (Sect. 38(1) of the Capital Markets Act) 3.114.318 Voting rights which the person subject to the notification obligation holds directly or indirectly (Sect. 38(1) of the Capital Markets Act) 4,8471 % Voting rights which the person subject to the notification obligation is entitled to acquire, dispose of or exercise (Sect. 38(2) of the Capital Markets Act 0 Voting rights which the person subject to the notification obligation is entitled to acquire, dispose of or exercise (Sect. 38(2) of the Capital Markets Act) 0,00 % SUBTOTAL 7.1.A Number of voting rights 3.114.318 Voting rights stated in % 4,8471 % 7.1.B: Share capital attached to shares 7.2 Financial instruments according to section 39(2)(1) of the Capital Markets Act 7.2.A: Voting rights attached to financial instruments according to section 39(2)(1) of the Capital Markets Act 7.2.B: Share capital attached to financial instruments according to section 39(2)(1) of the Capital Markets Act 7.3 Financial Instruments with similar economic effect acc. to sect. 39(2)(2) of the Capital Markets Act 7.3.A: Voting rights attached to financial instruments according to section 39(2)(2) of the Capital Markets Act 7.3.B: Share capital attached to financial instruments according to section 39(2)(2) of the Capital Markets Act
Shareholder Shareholder 3 / 3 Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity The person subject to the notification obligation is not controlled by any natural person or legal entity and does not xii control any undertaking(s) with holdings in the (underlying) issuer 8. Chain of controlled undertakings (please tick the appropriate box): Name Allan & Gill Gray Foundation Total voting rights if more than 5% Total share capital if more than 5% Name Orbis Allan Gray Limited Total voting rights if more than 5% Total share capital if more than 5% Name Orbis Holdings Limited Total voting rights if more than 5% Total share capital if more than 5% Name Orbis Investment Management Limited Total voting rights if more than 5% Total share capital if more than 5% 9. In case of proxy voting Name of the proxy holder % and number voting rights Date 10. Additional information Orbis Investment Management Limited is an investment manager which has investment discretion and voting control over the Genmab A/S shares and ADRs held by certain investment funds and portfolios. ⭐The reporting party guarantees the accuracy of the information provided.
FAQ
What is Orbis’ current ownership percentage in Genmab (GMAB)?
Orbis’ current holding corresponds to 4.8471% of Genmab’s voting rights. This percentage is calculated from 3,114,318 voting rights out of a total of 64,250,721 and is reported as a major shareholder position under Section 30 of the Danish Capital Markets Act.
How did Orbis’ Genmab (GMAB) voting rights change from the previous notification?
Orbis’ voting rights decreased from 5.0141% to 4.8471% of Genmab’s total voting rights. Both positions involve no voting rights through financial instruments, only directly attached to shares, and the change triggered a new major shareholder notification on April 13, 2026.
Who is the ultimate reporting party behind the Orbis holding in Genmab (GMAB)?
The notification lists the Allan & Gill Gray Foundation as the person subject to the notification obligation, with Orbis Investment Management Limited acting as investment manager. Orbis has investment discretion and voting control over Genmab shares and ADRs held by certain funds and portfolios.